Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez, +219

The Lancet Oncology

Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor +6

Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial

Françis Lévi, Rachid Zidani, Jean-Michel Vannetzel, +14

JNCI Journal of the National Cancer Institute

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi, +26

Modern Pathology

Her2 Scoring SystemColorectal SurgeryMedicineGastroenterologyColorectal Cancer +5

Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer

Pasquale F. Innominato, C. Focan, Thierry Gorlia, +13

Cancer Research

Biological CorrelateQuality Of LifeCancer ManagementPharmacotherapyOncology +19

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Sylvie Giacchetti, Georg A. Bjarnason, Carlo Garufi, +16

Journal of Clinical Oncology

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

Francis Lévi, B Perpoint, Carlo Garufi, +10

European Journal of Cancer

Circadian RhythmOxaliplatin ActivityGastrointestinal OncologyMedicinePhysiology +5

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini, +42

The Oncologist

ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy +19

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Daniele Santini, Bruno Vincenzi, Raffaele Addeo, +16

Annals of Oncology

Cetuximab RechallengeGastrointestinal OncologyMedicineImmunologyPathology +4

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

Carlo Garufi, Angela Torsello, Salvatore Tumolo, +7

British Journal of Cancer

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti, +32

Clinical Lung Cancer

Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials +7